NCT01826201View on ClinicalTrials.gov

Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Psoriasis
Interventions
DRUG

MOL4239

10% MOL4239 ointment to one target lesion twice a day for 28.5 consecutive days

DRUG

Placebo

placebo ointment to the contralateral target lesion twice a day for 28.5 consecutive days

Trial Locations (3)

33144

International Dermatology Research, Inc., Miami

55432

Minnesota Clinical Study Center, Fridley

87106

Academic Dermatology Associates, Albuquerque

All Listed Sponsors
lead

Moleculin, LLC

INDUSTRY

NCT01826201 - Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis | Biotech Hunter | Biotech Hunter